Exceptional revenue growth near 63% per year and three consecutive earnings beats demonstrate strong commercial momentum, but deeply negative free cash flow consuming roughly 89% of revenues, below-floor business quality, and a technical setup that has not yet confirmed a resumption of trend strength combine to limit the investable case despite the growth trajectory.
Thesis pillars
- Exceptional Revenue Growth Rate→Stable
- Improving Earnings Beat Cadence→Stable
- Severe Cash Burn Viability Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Kestra Medical Technologies, Lt (KMTS) Stock Analysis
Healthcare · Medical Instruments & Supplies
Wait for pullback to $21.38. At $23.18 the A.R:R is 1.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $21.38 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: ASSURE WCD; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1).
Kestra Medical Technologies develops and commercializes the ASSURE WCD, a wearable cardioverter defibrillator that monitors and treats patients at elevated risk of sudden cardiac arrest, as the cornerstone of its Cardiac Recovery System platform. The company generates revenue... Read more
Wait for pullback to $21.38. At $23.18 the A.R:R is 1.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $21.38 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: ASSURE WCD; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1). Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 1 day. Wait until post-earnings. Score 5.1/10, moderate confidence.
Passes 3/7 gates (no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and clean insider activity and earnings proximity 1d<=7d. Suitability: aggressive.
About Kestra Medical Technologies, Lt
About Kestra Medical Technologies, Lt
Kestra Medical Technologies' ASSURE wearable cardioverter defibrillator, cleared by the FDA in July 2021, generated nearly all of the company's revenue for the fiscal year ended April 30, 2025, when Kestra reported $59.8 million in revenue, up 115% from $27.8 million a year earlier. The company leases the ASSURE WCD to patients recovering from a myocardial infarction or heart failure, billing Medicare, Medicaid and private payors for wear time.
Kestra earns revenue by leasing the ASSURE WCD to patients on a month-to-month basis and billing third-party payors -- Medicare, Medicaid and private insurers -- for wear time, plus co-insurance and deductibles collected directly from patients. As of April 30, 2025, roughly 285 million U.S. lives were covered under contracts spanning traditional Medicare, select state Medicaid programs and national commercial insurers, representing about 90% of total available lives. The company sells through a direct commercial team of approximately 80 sales representatives and more than 40 clinical support staff, backed by a contracted network of over 300 patient specialists who fit and train device wearers. Devices are manufactured and reprocessed through partnerships with established medical-technology suppliers, and the fleet is reused across multiple patient wears per year. Kestra's only competitor is the incumbent WCD maker that held sole commercial availability in the category for more than two decades before the ASSURE WCD's approval.
Show full overview
Kestra's reimbursement is concentrated in a payer base where Medicare, Medicaid and commercial insurers together cover roughly 90% of the 285 million lives Kestra can bill under contract, so a shift in Medicare's payment rate for wearable defibrillator wear time would flow directly through revenue. Medicare reimbursement for WCD therapy rose at a 4.7% compound annual rate from 2021 to 2025, but the 10-K discloses no assurance that rates will hold at current levels, and a decrease in payor reimbursement or new coverage limitations could adversely affect results. Because nearly all revenue derives from the single ASSURE WCD product billed through this payor mix, any adverse rate-setting cycle affects the entire business rather than one product line among several.
See also: Healthcare · Medical Instruments & Supplies
From Kestra Medical Technologies, Lt's most recent 10-K filing, extracted September 6, 2026.
Recent developments
updated 2026-09-13Recent Developments — Kestra Medical Technologies, Lt
Latest news
- NEWS Kestra Medical Technologies Appoints Daniel Finney as Vice President of Research & Development - Quiver Quantitative — Quiver Quantitative positive
- NEWS Kestra Medical Technologies Appoints Daniel Finney as Vice President of Research & Development - quiverquant.com — quiverquant.com positive
- NEWS KESTRA MEDICAL TECHNOLOGIES Q1 2027 Earnings Preview: Recent $KMTS Insider Trading, Hedge Fund Activity, and More - Quiv — Quiver Quantitative neutral
- NEWS KESTRA MEDICAL TECHNOLOGIES Q1 2027 Earnings Preview: Recent $KMTS Insider Trading, Hedge Fund Activity, and More - quiv — quiverquant.com neutral
- NEWS Analysts Estimate Kestra Medical Technologies, Ltd. (KMTS) to Report a Decline in Earnings: What to Look Out for - Yahoo — Yahoo Finance negative
Generated 2026-09-14T05:21:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductASSURE WCD10-K Item 1A: 'We are therefore highly dependent on our ASSURE WCD for our continued success. ... will continue to account for nearly all of our revenue for the foreseeable future.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $21.38. At $23.18 the A.R:R is 1.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $21.38 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: ASSURE WCD; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1). Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 1 day. Wait until post-earnings. Target $26.10 (+12.6%), stop $18.99 (−22.1%), A.R:R 1.4:1. Score 5.1/10, moderate confidence.
Take-profit target: $26.10 (+14.2% upside). Target $26.10 (+12.6%), stop $18.99 (−22.1%), A.R:R 1.4:1. Stop-loss: $18.99.
Concentration risk — Product: ASSURE WCD; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1); Expensive valuation.
Kestra Medical Technologies, Lt trades at a P/E of N/A (forward -11.3). TrendMatrix value score: 3.8/10. Verdict: Buy (Wait for Entry).
14 analysts cover KMTS with a consensus score of 4.3/5. Average price target: $30.
What does Kestra Medical Technologies, Lt do?Kestra Medical Technologies develops and commercializes the ASSURE WCD, a wearable cardioverter defibrillator that...
Kestra Medical Technologies develops and commercializes the ASSURE WCD, a wearable cardioverter defibrillator that monitors and treats patients at elevated risk of sudden cardiac arrest, as the cornerstone of its Cardiac Recovery System platform. The company generates revenue primarily by leasing the ASSURE WCD to patients on a month-to-month basis and billing Medicare, Medicaid and private payors, reporting $59.8 million in revenue for the fiscal year ended April 30, 2025. Kestra competes against a single incumbent WCD maker that held sole commercial availability in the category for more than